Showing 6051-6060 of 7865 results for "".
- Artemis Health, Zerigo Health Partner to Help Employers and Health Plans Better Evaluate and Manage Chronic Autoimmune Skin Conditionshttps://practicaldermatology.com/news/artemis-health-zerigo-health-partner-to-help-employers-and-health-plans-better-evaluate-and-manage-chronic-autoimmune-skin-conditions/2461335/Artemis Health and Zerigo Health are joining forces to helps employers, advisors, and health plans evaluate and manage benefits for their members with chronic autoimmune skin conditions such as psoriasis and atopic dermatitis. “Benefits leaders are inundated by hundreds of point s
- EADV 2022 News: Otezla Works Well in Kids with PsO, Adults with Genital PsOhttps://practicaldermatology.com/news/eadv-2022-news-otezla-works-well-in-kids-with-pso-adults-with-genital-pso/2461332/Otezla (apremilast) performs well in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, according to new research presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress in Milan, Italy. 
- Daxxify from Revance Gets FDA Greenlighthttps://practicaldermatology.com/news/daxxify-from-revance-gets-fda-greenlight/2461331/Daxxify™ (DaxibotulinumtoxinA-lanm) from Revance is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults. Daxxify is the first and only neuromodulator stabilized with Peptide Exchange Technology™ (PXT) and is free of both human serum
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail
- EADV News: Tape Strip Test May Predict Eczema Risk in Babieshttps://practicaldermatology.com/news/eadv-news-tape-strip-test-may-predict-eczema-risk-in-babies/2461329/An immune biomarker in newborns may predict the subsequent onset and severity of paediatric atopic eczema, according to a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress. The Barrier dysfunction in Atopic newBorns (BABY) study analyzed a c
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- Arcutis Rolls Out New Psoriasis Public Awareness Campaignhttps://practicaldermatology.com/news/arcutis-rolls-out-new-psoriasis-public-awareness-campaign/2461321/Arcutis Biotherapeutics, Inc. is launching an educational campaign designed to raise awareness about the physical and emotional impact of plaque psoriasis and empower those living with the disease to have open, honest conversations with their healthcare providers, family, and friends.
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions
- Cutera Recognized by 50/50 Women on Boards for Gender-Balanced Board of Directorshttps://practicaldermatology.com/news/cutera-recognized-by-5050-women-on-boards-for-gender-balanced-board-of-directors/2461315/The 50/50 Women on Boards recognized Cutera for having a gender-balanced board. With four women directors, holding 50 percent of its corporate board seats, Cutera, Inc. is one of only 8 percent (just 241) of Russell 3000 companies with a gender-balanced board. &ldq
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu